Reviewer’s report

Title: Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate

Version: 1 Date: 31 Oct 2018

Reviewer: Peter Penson

Reviewer’s report:

Thank you for making the suggested revisions to the papers. Having read the revised version, I have the following comments:

-Thank you for clarifying in your manuscript that CKD= GFR<60 ml/min in your paper (as suggested by the previous reviewer. However, I think that the continued use of "GFR,60 ml/min/1.73m2" in the text and title disrupts the flow of the text for the reader. Instead, Please consider amending this to read "CKD" or "low GFR" (or similar) in the text, and make clear in the text and the discussion make clear that your patients with GFR<60 cannot be assumed to be representative of the CKD population in general.

-In line 139 , please explain/expand on the term "(Enter)"

-In your discussion, please mention the limitation of residual confounding which applies to all observational studies.

-Please have the whole manuscript (especially the new sections) proofread by an English language editing service or native speaker, the grammar and syntax are still hard to follow in places

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I own four shares in AstraZeneca PLC, and I have received speaker's fees from Amgen Inc.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal